MAP2K7 and neurofibromatosis type 1: 32272491 32272491 Klesse LJ, Jordan JT, Radtke HB et al (2020) The Use of MEK Inhibitors in Neurofibromatosis Type 1—Associated Tumors and Management of Toxicities.